近日，中恒集团披露了第十五份《社会责任报告》，展示了其在乡村振兴、推动绿色低碳转型、保障民 生福祉等领域的实践，年度内获评国有企业上市公司ESG·先锋100指数、中国上市公司协会2024可持续 发展优秀实践案例等多项荣誉。 深耕绿色发展，推进低碳转型进程。中恒集团以国家"双碳"目标为导向，持续在节能减排、清洁生产、 可再生能源利用等方面投入。推广绿色防控与仿野生种植技术，筹建国家二级保护植物金毛狗脊救护基 地，形成中草药"生产实践—生态救护"绿色生态圈；通过开展"世界环境日""植树造林"等活动，将环保 理念向社会维度延伸。 转自：新华财经 编辑：穆皓 未来，中恒集团将一如既往保持务实底色，携手合作伙伴，以产业建设为基石，以国企改革为动力，以 守护人民健康为己任，为全面深化改革、推进中国式现代化积极贡献中恒集团的智慧与力量。（许华 瑜） 践行国企担当，赋能民生健康保障。中恒集团积极响应国家政策，多个产品续约或中标国家级、省级集 采，两款核心产品纳入医保目录，助力临床用药可及性的提升，切实减轻患者用药负担；探索"产业 +科技+公益"乡村振兴融合模式，支持中药材基地建设，带动农户增收；利用驻点帮扶村优势，整合非 物 ...

证券代码：000931 证券简称：中关村 答：尊敬的投资者，您好！随着老龄人口的增加和高血压患病人群的 年轻化趋势，抗高血压药物的市场需求会持续增长。 北京中关村科技发展（控股）股份有限公司 投资者关系活动记录表 编号：2025-002 投资者关系 活动类别 特定对象调研 分析师会议 媒体采访 业绩说明会 新闻发布会 路演活动 现场参观 其他 活动参与人员 线上参与公司 2024 年度暨 2025 年第一季度业绩说明会的全体投资者 时间 2025 年 5 月 12 日 地点 价值在线（https://eseb.cn/1nQhfVk8kzm）网络互动 形式 网络文字互动方式 上市公司接待 人员姓名 董事兼总裁：侯占军 独立董事：史录文、毕克 副总裁：李斌 副总裁兼董事会秘书：黄志宇 副总裁兼财务总监：宋学武 1 一、请问侯总，围绕后续发展战略，公司未来 3 到 5 年将如何分配资 源？是否考虑剥离非核心资产？ 答：尊敬的投资者，您好！公司正秉承聚焦医药大健康主业、剥离非 医药业务的总体经营战略。公司会综合考量现有沉淀的存量资产和非医药 业务的自身发展状况、市场环境的变化趋势以及行业动态等多种因素，审 慎选择合适 ...

Core Viewpoint - The company has reported its first-quarter financial results for 2025, highlighting significant developments in product approvals and strategic initiatives aimed at enhancing operational efficiency and shareholder returns [12][28]. Financial Data - The company achieved a revenue of 3.215 billion yuan and a net profit attributable to shareholders of 133 million yuan in 2024 [12]. - The company plans to distribute a cash dividend of 0.98 yuan per 10 shares for the 2024 fiscal year, totaling approximately 107 million yuan, maintaining a cash dividend ratio of 80.18% [15]. Product Approvals and Market Expansion - The company received approval for the active pharmaceutical ingredient (API) Fumarate Formoterol and the inhalation solution from the National Medical Products Administration, which is expected to enhance its market presence [5]. - The company’s Dexamethasone Sodium Phosphate API has been approved for sale in Brazil, which will aid in expanding its international market footprint [5]. - The company obtained a production license for special dietary foods covering 26 amino acids, enhancing its operational capabilities [5]. Research and Development - In 2024, the company invested 248 million yuan in R&D, representing 7.7% of its main business revenue, and achieved significant milestones in drug approvals [16]. - The company plans to focus on six key areas, including ophthalmology and dermatology, to enhance its product pipeline and market competitiveness [17]. Compliance and Governance - The company is committed to enhancing its compliance management systems and has implemented various measures to improve operational efficiency and risk management [18][22]. - The company has revised its governance documents to align with regulatory requirements and improve its response to public sentiment [22]. Investor Relations - The company emphasizes the importance of information disclosure and has actively engaged with investors through various channels, including regular reports and investor education initiatives [20][21]. - The company has received a B-level rating for information disclosure from the Shanghai Stock Exchange, reflecting its commitment to transparency [20].

Core Viewpoint - Beijing Zhongguancun Science and Technology Development (Holding) Co., Ltd. announced that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., has been selected in the 10th batch of national drug centralized procurement for its product, Naloxone Hydrochloride Injection, which is expected to positively impact the company's future performance and market presence [1][2]. Group 1: Product Information - Product Name: Naloxone Hydrochloride Injection - Dosage Form: Injection - Specification: 1ml:1mg - Packaging: 10 vials/box - Indications: Used for reversing respiratory depression caused by opioid drugs, treating opioid overdose, and diagnosing acute opioid overdose [1][2]. Group 2: Procurement Details - Selected Price: 0.99 yuan per vial - Supply Provinces: Inner Mongolia, Liaoning, Jilin, Hunan, Qinghai - Backup Supply Provinces: Beijing, Tianjin, Zhejiang, Anhui, Jiangxi - Selected Company: Beijing Huasu Pharmaceutical Co., Ltd. [2]. Group 3: Impact on the Company - The selected product is classified as a Class A product under the national medical insurance scheme, with a procurement period from the selection date until December 31, 2027 - Medical institutions will prioritize the use of selected products, which is expected to enhance the company's sales channels and market share for Naloxone Hydrochloride Injection - The successful implementation of procurement contracts will contribute positively to the company's operational performance and long-term development [2].

津药药业股份有限公司关于子公司获得药品注册证 书的公告 证券代码：600488 证券简称：津药药业 编号：2025-014 津药药业股份有限公司关于子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 近日，津药药业股份有限公司（以下简称"公司"）子公司湖北津药药业股份有限公司（以下简称"湖北 津药"）收到国家药品监督管理局核准签发的关于盐酸纳洛酮注射液（以下简称"该药品"或"本品"）的 《药品注册证书》。现将相关情况公告如下： 盐酸纳洛酮注射液为阿片类受体拮抗药。湖北津药于2023年8月向国家药品监督管理局药品审评中心提 交该药品注册申请并获受理。截至目前，湖北津药在该药品研发项目上已累计投入约420万元。 三、同类药品市场情况 根据米内网全国放大版的医院数据（含城市公立医院、县级公立医院、城市社区医院、乡镇卫生院）显 示，2022年、2023年盐酸纳洛酮注射液国内销售额分别为4.13亿元、5.35亿元。 四、对上市公司影响及风险提示 湖北津药盐酸纳洛酮注射液获得《药品注册证书》，完善了公司制剂 ...